The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells

References

• Arabski, M., Kazmierczak, P., Wisniewska-Jarosinska, M., Poplawski, T., Klupinska, G., Chojnacki, J., et al. (2005). Interaction of amoxicillin with DNA in human lymphocytes and H. pylori-infected and non-infected gastric mucosa cells. Chem Biol Interact 152:13–24.
   PubMed Web of Science ®Google Scholar
• Blask, D. E., Dauchy, R. T., Sauer, L. A. (2005). Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 27:179–188.
   PubMed Web of Science ®Google Scholar
• Burgess, D. J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W. R., et al. (2008). Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 105:9053–9058.
   PubMed Web of Science ®Google Scholar
• Carpentieri, A., Díaz de Barboza, G., Areco, V., Peralta López, M., Tolosa de Talamoni, N. (2012). New perspectives in melatonin uses. Pharmacol Res 65:437–444.
   PubMed Web of Science ®Google Scholar
• Casado-Zapico, S., Rodriguez-Blanco, J., Garcia-Santos, G., Martin, V., Sanchez-Sanchez, A. M., Antolin, I., et al. (2010). Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J Pineal Res 48:72–80.
   PubMed Web of Science ®Google Scholar
• Cemeli, E., Baumgartner, A., Anderson, D. (2009). Antioxidants and the comet assay. Mutat Res 681:51–67.
   PubMed Web of Science ®Google Scholar
• Cerea, G., Vaghi, M., Ardizzoia, A., Villa, S., Bucovec, R., Mengo, S., et al. (2003). Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res 23:1951–1954.
   PubMed Web of Science ®Google Scholar
• Cos, S., Mediavilla, M. D., Fernandez, R., Gonzalez-Lamuno, D., Sanchez-Barcelo, E. J. (2002). Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? J Pineal Res 32:90–96.
   PubMed Web of Science ®Google Scholar
• Cucina, A., Proietti, S., D’Anselmi, F., Coluccia, P., Dinicola, S., Frati, L., et al. (2009). Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res 46:172–180.
   PubMed Web of Science ®Google Scholar
• Da Violante, G., Zerrouk, N., Richard, I., Provot, G., Chaumeil, J. C., Arnaud, P. (2002). Evaluation of the cytotoxicity effect of dimethyl sulfoxide (DMSO) on Caco2/TC7 colon tumor cell cultures. Biol Pharm Bull 25:1600–1603.
   PubMed Web of Science ®Google Scholar
• de Jong, F. A., Mathijssen, R. H., Xie, R., Verweij, J., Sparreboom, A. (2004). Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 10:4068–4071.
   PubMed Web of Science ®Google Scholar
• Dhawan, A., Bajpayee, M., Parmar, D. (2009). Comet assay: a reliable tool for the assessment of DNA damage in different models. Cell Biol Toxicol 25:5–32.
   PubMed Web of Science ®Google Scholar
• Dudas, A., Chovanec, M. (2004). DNA double-strand break repair by homologous recombination. Mutat Res 566:131–167.
   PubMed Web of Science ®Google Scholar
• Evans, W. E., McLeod, H. L. (2003). Pharmacogenomics: drug disposition, drug targets, and side effects. New Engl J Med 348:538–549.
   PubMed Web of Science ®Google Scholar
• Fan, L. L., Sun, G. P., Wei, W., Wang, Z. G., Ge, L., Fu, W. Z., et al. (2010). Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World J Gastroenterol 16:1473–1481.
   PubMed Web of Science ®Google Scholar
• Garcia-Santos, G., Antolin, I., Herrera, F., Martin, V., Rodriguez-Blanco, J., del Pilar Carrera, M., et al. (2006). Melatonin induces apoptosis in human neuroblastoma cancer cells. J Pineal Res 41:130–135.
   PubMed Web of Science ®Google Scholar
• Grabarz, A., Barascu, A., Guirouilh-Barbat, J., Lopez, B. S. (2012). Initiation of DNA double strand break repair: signaling and single-stranded resection dictate the choice between homologous recombination, non-homologous end-joining, and alternative end-joining. Am J Cancer Res 2:249–268.
   Web of Science ®Google Scholar
• Hefferin, M. L., Tomkinson, A. E. (2005). Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair (Amst.) 4:639–648.
   PubMed Web of Science ®Google Scholar
• Jung, B., Ahmad, N. (2006). Melatonin in cancer management: progress and promise. Cancer Res 66:9780–9793.
   Google Scholar
• Kasparek, T. R., Humphrey, T. C. (2011). DNA double-strand break repair pathways, chromosomal rearrangements, and cancer. Semin Cell Dev Biol 22:886–897.
   PubMed Web of Science ®Google Scholar
• Kim, C., Kim, N., Joo, H., Youm, J. B., Park, W. S., Cuong, D. V., et al. (2005). Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. J Cardiovasc Pharmacol 46:200–210.
   PubMed Web of Science ®Google Scholar
• Kim, J. H., Jeong, S. J., Kim, B., Yun, S. M., Choido, Y., Kim, S. H. (2012). Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells. J Pineal Res 52:244–252.
   PubMed Web of Science ®Google Scholar
• Końca, K., Lankoff, A., Banasik, A., Lisowska, H., Kuszewski, T., Góźdź, S., et al. (2003). A cross-platform public domain PC image-analysis program for the comet assay. Mutat Res 534:15–20.
   PubMed Web of Science ®Google Scholar
• Kontek, R., Drozda, R., Sliwinski, M., Grzegorczyk, K. (2010). Genotoxicity of irinotecan and its modulation by vitamins A, C, and E inhuman lymphocytes from healthy individuals and cancer patients. Toxicology in Vitro 24:417–424.
   PubMed Web of Science ®Google Scholar
• Kopjar, N., Źeljeźić, D., Vrdoljak, A. L., Radić, B., Ramić, S., Milić, M., et al. (2007). Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers. Nordic Pharmacological Society. Basic Clin Pharmacol Toxicol 100:403–413.
   PubMed Web of Science ®Google Scholar
• Korkmaz, A., Reiter, R. J., Topal, T., Manchester, L. C., Oter, S., Tan, D. X. (2009). Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 15:43–50.
   PubMed Web of Science ®Google Scholar
• Leon-Blanco, M. M., Guerrero, J. M., Reiter, R. J. (2003). Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res 35:204–211.
   PubMed Web of Science ®Google Scholar
• Liao, W., McNutt, M. A., Zhu, W.-G. (2009). The comet assay: a sensitive method for detecting DNA damage in individual cells. Methods 48:46–53.
   PubMed Web of Science ®Google Scholar
• Lissoni, P., Chilelli, M., Villa, S., Cerizza, L., Tancini, G. (2003). Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 35:12–15.
   PubMed Web of Science ®Google Scholar
• Majsterek, I., Gloc, E., Blasiak, J., Reiter, R. J. (2005). A comparison of the action of amifostine and melatonin on DNA-damaging effects and apoptosis induced by idarubicin in normal and cancer cells. J Pineal Res 38:254–263.
   PubMed Web of Science ®Google Scholar
• Mao, L., Cheng, Q., Guardiola-Lemaitre, B., Schuster-Klein, C., Dong, C., Lai, L., et al. (2010). In vitro and in vivo antitumor activity of melatonin receptor agonists. J Pineal Res 49:210–221.
   PubMed Web of Science ®Google Scholar
• Mathijssen, R. H., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., et al. (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182–2194.
   PubMed Web of Science ®Google Scholar
• Mathijssen, R. H., Verweij, J., de Jonge, M. J., Nooter, K., Stoter, G., Sparreboom, A. (2002). Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 20:81–87.
   PubMed Web of Science ®Google Scholar
• Matlawska-Wasowska, K., Rainczuk, K., Kalinowska-Lis, U., Osiecka, R., Ochocki, J. (2007). Genotoxicity of novel trans-platinum(II) complex with diethyl (pyridin-4-ylmethyl)phosphate in human non-small cell lung cancer cells 549. Chem Biol Interact 168:135–142.
   PubMed Web of Science ®Google Scholar
• Messina, G., Lissoni, P., Marchiori, P., Bartolacelli, E., Brivio, F., Magotti, L. (2010). Enhancement of the efficacy of cancer chemotherapy by the pineal hormone melatonin and its relation with the psychospiritual status of cancer patients. J Res Med Sci 15:225–228.
   Web of Science ®Google Scholar
• Mills, E., Wu, P., Mills, E., Wu, P., Seely, D., Guyatt, G. (2005). Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 39:360–366.
   PubMed Web of Science ®Google Scholar
• Möller, P. (2005). Genotoxicity of environmental agents assessed by the alkaline comet assay. Basic Clin Pharmacol Toxicol 96(Suppl 1):1–42.
   PubMedGoogle Scholar
• Möller, P. (2006). The alkaline comet assay: towards validation in biomonitoring of DNA damaging exposures. Basic Clin Pharmacol Toxicol 98:336–345.
   PubMed Web of Science ®Google Scholar
• Pant, H. H., Rao, M. V. (2010). Evaluation of in vitro anti-genotoxic potential of melatonin against arsenic and fluoride in human blood cultures. Ecotoxicol Environ Saf 73:1333–1337.
   PubMed Web of Science ®Google Scholar
• Paternoster, L., Radogna, F., Accorsi, A., Cristina Albertini, M., Gualandi, G., Ghibelli, L. (2009). Melatonin as a modulator of apoptosis in B-lymphoma cells. Ann N Y Acad Sci 1171:345–349.
   PubMed Web of Science ®Google Scholar
• Pavillard, V., Agostini, C. Richard, S., Charasson, V., Montaudon, D., Robert, J. (2002). Determinant of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol 49:329–335.
   PubMed Web of Science ®Google Scholar
• Pelicano, H., Carney, D., Huang, P. (2004). ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7:97–110.
   PubMed Web of Science ®Google Scholar
• Poplawski, T., Pastwa, E., Blasiak, J. (2010). Non-homologous DNA end joining in normal and cancer cells and its dependence on break structures. Genet Mol Biol 33:368–373.
   PubMed Web of Science ®Google Scholar
• Reiter, R. J., Tan, D. X., Sainz, R. M., Mayo, J. C., Lopez-Burillo, S. (2002). Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 54:1299–1321.
   PubMed Web of Science ®Google Scholar
• Reiter, R. J. (2003). Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 17:273–285.
   PubMed Web of Science ®Google Scholar
• Reiter, R. J. (2004). Mechanisms of cancer inhibition by melatonin. J Pineal Res 37:213–214.
   PubMed Web of Science ®Google Scholar
• Rubio, S., Estevez, F., Cabrera, J., Reiter, R. J., Loro, J., Quintana, J. (2007). Inhibition of proliferation and induction of apoptosis by melatonin in human myeloid HL-60 cells. J Pineal Res 42:131–138.
   PubMed Web of Science ®Google Scholar
• Sanchez-Barcelo, E. J., Mediavilla, M. D., Alonso-Gonzalez, C., Reiter, R. J. (2012). Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin Investig Drugs 21:819–831.
   PubMed Web of Science ®Google Scholar
• Sapra, P., Zhao, H., Mehlig, M., Malaby, J., Kraft, P., Longley, C., et al. (2008). Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res 14:1888–1896.
   PubMed Web of Science ®Google Scholar
• Singh, N. P., McCoy, T., Tice, R. R., Schneider, E. L. (1988). A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184–192.
   PubMed Web of Science ®Google Scholar
• Sliwinski, T., Rozej, W., Morawiec-Bajda, A., Morawiec, Z., Reiter, R. J., Blasiak, J. (2007). Protective action of melatonin against oxidative DNA damage: chemical inactivation versus base-excision repair. Mutat Res 634:220–227.
   PubMed Web of Science ®Google Scholar
• Slupianek, A., Hoser, G., Majsterek, I., Bronisz, A., Malecki, M., Blasiak, J., et al. (2002). Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 22:4189–4201.
   PubMed Web of Science ®Google Scholar
• Smith, N. F., Figg, W. D., Sparreboom, A. (2006). Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicology in Vitro 20:63–75.
   PubMedGoogle Scholar
• Speit, G., Hartmann, A. (2005). The comet assay: a sensitive genotoxicity test for the detection of DNA damage. Methods Mol Biol 291:85–95.
   PubMedGoogle Scholar
• Taylor, R. R., Tang, Y., Gonzalez, M. V., Stratford, P. W., Lewis, A. L. (2007). Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 30:7–14.
   PubMed Web of Science ®Google Scholar
• Teicher, B. A. (2008). Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 75:1262–1271.
   PubMed Web of Science ®Google Scholar
• Tice, R. R., Agurell, E., Anderson, D., Burlinson, B., Hartmann, A., Kobayashi, H., et al. (2000). Single gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206–221.
   PubMed Web of Science ®Google Scholar
• Trubiani, O., Recchioni, R., Moroni, F., Pizzicannella, J., Caputi, S., Di Primio, R. (2005). Melatonin provokes cell death in human B-lymphoma cells by mitochondrial-dependent apoptotic pathway activation. J Pineal Res 39:425–431.
   PubMed Web of Science ®Google Scholar
• Vaskova, J., Kassayova, M., Vasko, L. (2011). Potential role of melatonin in DNA damage caused by nitrosourea-induced mammary carcinogenesis. Acta Histochem 113:423–427.
   PubMed Web of Science ®Google Scholar
• Zupancic, D., Jezernik, K., Vidmar, G. (2008). Effect of melatonin on apoptosis, proliferation, and differentiation of urothelial cells after cyclophosphamide treatment. J Pineal Res 44:299–306.
   PubMed Web of Science ®Google Scholar